View settings

Font size:
Site colours:


Official website of the President of Russia


The 2019 National Awards in Science and Technology have been conferred on Dmitry Morozov, Andrei Ulitin, and Tatyana Chernovskaya for developing and introducing into clinical practice a complex of medicinal preparations based on monoclonal antibodies to treat cancer and autoimmune diseases

June 18, 2020

Dmitry Morozov was born on February 1, 1965 in Moscow and is Director General of BIOCAD.

Andrei Ulitin was born on April 3, 1974 in Kuibyshev and is Acting Research Fellow at the Institute for Biological Instrumentation of the Russian Academy of Sciences.

Tatyana Chernovskaya was born on August 12, 1951 in Sosnogorsk, Komi ASSR. BSc, Director of the Biochemistry Department at BIOCAD.

For the first time in Russia, researchers have created a unique scientific and industrial complex of ready dosage forms of monoclonal antibodies to treat malignant and autoimmune diseases, which fully meets Russia’s needs. The biotechnological (MabNext) and bioinformatical (YLab) platforms they developed surpass their foreign analogues and allow faster production of immunotherapeutic medicines, which makes medical aid more readily available.

Dmitry Morozov founded the only scientific and industrial complex to develop and produce monoclonal antibodies in Russia, which is also the first in Eastern Europe. He is the ideologist of the biotechnological (MabNext) and bioinformatical (YLab) platforms.

Andrei Ulitin is a major expert in the genetic engineering of expression systems and the production of therapeutic monoclonal antibodies. He directed the creation of the MabNext biotechnological platform that helps to quickly develop medical agents from concept to pre-clinical trial (over the last four years, three drugs were developed and implemented in Russia and another two have passed state registration trials).

Tatyana Chernovskaya is a leading specialist in the biochemistry of protein compounds. She directly led the development of technologies to isolate high purity proteins and monoclonal antibodies for medicines.